The Commission approved 225 projects under the Technical Support Instrument (TSI), to support Member States in preparing, designing and implementing reforms that will lead to modern and resilient public administrations, sustainable growth strategies and resilient economies while enhancing their capacity to react to current and future crises. The 2022 TSI Work Programme also includes some novelties like the multi-country or multi-region projects, as well as the flagship projects.
More than 1 in 7 adults in Europe experience a high-pitched ringing in the ears called tinnitus, according to a recent study supported by the EU-funded ESIT, UNITI and GENDER NET Plus projects. The current study is most likely the first of its kind to have collected multinational data on tinnitus using the same standardised survey questions and response options across 12 European countries.
The Innovative Medicines Initiative’s European Lead Factory, a screening service with a vast chemical library, has helped identify two drug candidates for cancer treatment that have now progressed to clinical testing. An Israeli SME called Metabomed and the German pharmaceutical company Merck KGaA, have both recently identified compounds in ELF’s high-quality compound collection that show promise in inhibiting their target pathways, both of which are involved in the development of tumours.
The European Liquid Biopsy Society, an offshoot of the IMI project CANCER-ID, is pushing the science on liquid biopsies closer to clinical reality. The ability to detect and study tumours through a mere blood sample – a minimally invasive procedure – would have huge implications, and a lot of progress has been made in the development of different technologies that achieve this ambitious goal.
On Monday 31st January, the assessment and supervision of clinical trials throughout the EU was harmonised, notably via a Clinical Trials Information System (CTIS) run by the European Medicines Agency. From this date the Regulation on Clinical Trials have entered into application. This Regulation improves conducting clinical trials in the EU, with the highest standards of safety for participants and increased transparency of trial information.
Physician-scientists in the Smidt Heart Institute at Cedars-Sinai have created an artificial intelligence (AI) tool that can effectively identify and distinguish between hypertrophic cardiomyopathy and cardiac amyloidosis, two life-threatening heart conditions that are often easy to miss. The two-step, novel algorithm identifies specific features - related to the thickness of heart walls and the size of heart chambers - to efficiently flag certain patients as suspicious for having the potentially unrecognized cardiac diseases.
The Health Effects Institute has conducted a research which has documented associations between early life air pollution exposure and various measures of brain structural morphology, structural connectivity, and functional connectivity in children. But further analyses in this topic are encouraged.
Following the adoption of the 2022 work plan by the HERA Board, HERA can now start implementing actions to strengthen preparedness and response capabilities within the EU, address vulnerabilities and strategic dependencies and contribute to reinforcing the global health emergency architecture.
As of Monday 31 January, the assessment and supervision of clinical trials throughout the EU will be harmonised, notably via a Clinical Trials Information System (CTIS) run by the European Medicines Agency. On this date the Regulation on Clinical Trials will enter into application. This Regulation will improve conducting clinical trials in the EU, with the highest standards of safety for participants and increased transparency of trial information
Researchers supported by the EU-funded LUCA, VASCOVID and LASERLAB-EUROPE projects studied COVID-19 from a different perspective. In what is likely the first study of its kind, they examined how the disease affected microcirculation – the circulation of blood in the smallest blood vessels – in seriously ill COVID-19 patients.
In 2022, the EU4Health will continue to invest in building stronger, more resilient health systems and pave the way for the European Health Union. With a budget of over €835 million, the new work programme will provide an unparalleled level of EU investment in health and ensure ambitious and decisive action in four focus areas: crisis preparedness, disease prevention, health systems and healthcare workforce, and digitalisation.